18. 脊髄小脳変性症(多系統萎縮症を除く。) [臨床試験数:59,薬物数:78(DrugBank:28),標的遺伝子数:44,標的パスウェイ数:59

Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02705547May 20165/3/2016Rosuvastatin (Crestor) in Friedreich AtaxiaOpen-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich AtaxiaFriedreich AtaxiaDrug: RosuvastatinChildren's Hospital of PhiladelphiaFriedreich's Ataxia Research AllianceCompleted18 Years65 YearsAll12Early Phase 1United States